LCG
PBYI icon

Lisanti Capital Growth’s Puma Biotechnology PBYI Stock Holding History

Lisanti Capital Growth’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,155
Closed -$1.47M – 100
2014
Q3 		$1.47M Buy
+6,155
New +$1.26M 0.74% 63

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Lisanti Capital Growth's PBYI Position: Q4 2014 in Review

Lisanti Capital Growth sold out of Puma Biotechnology (PBYI) in Q4 2014, closing a stake of 6,155 shares — an estimated $1.47M sold.

Lisanti Capital Growth first reported a position in PBYI in Q3 2014 and held it in 1 quarter. The position peaked at $1.47M in Q3 2014. 189 funds tracked by Wall St. Rank hold PBYI as of Q4 2014.

  • Lisanti Capital Growth reported no remaining Puma Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Lisanti Capital Growth sold 6,155 Puma Biotechnology shares in Q4 2014, an estimated $1.47M.
  • Lisanti Capital Growth first reported a position in Puma Biotechnology in Q3 2014 and held it in 1 quarter.
  • Lisanti Capital Growth's Puma Biotechnology position peaked at $1.47M in Q3 2014.
  • 189 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2014.

Based on Lisanti Capital Growth's 13F filing for Q4 2014, filed 10 Feb 2015.